Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
Add more filters










Publication year range
1.
Eur J Pharm Biopharm ; 169: 12-19, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34508807

ABSTRACT

In preclinical drug development, ex vivo and in vitro permeability studies are a decisive element for specifying subsequent development steps. In this context, reliability, physiological alignment and appropriate in vivo correlation are mandatory for predictivity regarding drug absorption. Especially in oromucosal drug delivery, these prerequisites are not adequately met, which hinders its progressive development and results in the continuous need for animal experiments. To address current limitations, an innovative, standardized, and controlled ex vivo permeation model was applied. It is based on Kerski diffusion cells embedded in automated sampling and coupled to mass spectrometric quantification under physiologically relevant conditions. This study aimed to evaluate the predictivity of the developed model using porcine mucosa (ex vivo) in relation to data of sublingual propranolol absorption (in vivo). In addition, the usefulness of biomimetic barriers (in vitro) as a replacement for porcine mucosa was investigated. Therefore, solubility and permeability studies considering microenvironmental conditions were conducted and achieved good predictivity (R2 = 0.997) for pH-dependent permeability. A multiple level C correlation (R2 ≥ 0.860) between obtained permeability and reported pharmacokinetic animal data (AUC, Cmax) was revealed. Furthermore, a point-to-point correlation was demonstrated for several sublingual formulations. The successful IVIVC confirms the standardized ex vivo model as a viable alternative to animal testing for estimating the in vivo absorption behavior of oromucosal pharmaceuticals.


Subject(s)
Oral Mucosal Absorption/physiology , Propranolol/pharmacokinetics , Administration, Sublingual , Adrenergic beta-Antagonists/pharmacokinetics , Animals , Drug Development/methods , Drug Evaluation, Preclinical/methods , Models, Animal , Mouth Mucosa/physiology , Permeability , Swine
2.
Int J Pharm ; 584: 119411, 2020 Jun 30.
Article in English | MEDLINE | ID: mdl-32423876

ABSTRACT

The aim of this study was to formulate an easily-administered, safe and effective dosage form loaded with meclizine for treatment of chemotherapy-induced nausea and vomiting (CINV) through the buccal route. CINV comprises bothersome side effects accompanying cytotoxic drugs administration in cancer patients. Meclizine was loaded in chitosan-pectin nanoparticles which were further incorporated within a buccal film. Different formulations were prepared based on a 21.31 full factorial study using Design Expert®8. The optimum formulation possessed favorable characters regarding its particle size (129 nm), entrapment efficiency (90%) and release profile. Moreover, its permeation efficiency through sheep buccal mucosa was assessed via Franz cell diffusion and confocal laser microscopy methods. Enhanced permeation was achieved compared with the free drug form. In-vivo performance was assessed using cyclophosphamide induced emesis. The proposed formulation exerted significant relief of the measured responses (reduced body weight and motor coordination, elevated emesis, anorexia, proinflammatory mediators and neurotransmitters that were also associated with scattered degenerated neurons and glial cells). The developed formulation ameliorated all behavioral, biochemical and histopathological changes induced by cyclophosphamide. The obtained data were promising suggesting that our bioadhesive formulation can offer an auspicious medication for treating distressing symptoms associated with chemotherapy for cancer patients.


Subject(s)
Antiemetics/pharmacology , Chitosan/chemistry , Meclizine/pharmacology , Nanoparticles/chemistry , Pectins/chemistry , Vomiting/drug therapy , Administration, Buccal , Animals , Antiemetics/administration & dosage , Antiemetics/pharmacokinetics , Antineoplastic Agents/adverse effects , Chemistry, Pharmaceutical/methods , Cyclophosphamide/adverse effects , Cytokines/biosynthesis , Delayed-Action Preparations , Drug Carriers/administration & dosage , Drug Carriers/pharmacology , Drug Liberation , Humans , Hydrogen-Ion Concentration , Inflammation Mediators/metabolism , Male , Meclizine/administration & dosage , Meclizine/pharmacokinetics , Microscopy, Electron, Transmission , Neurotransmitter Agents/metabolism , Oral Mucosal Absorption/physiology , Rats , Rats, Wistar , Sheep , Spectroscopy, Fourier Transform Infrared , Tensile Strength , Vomiting/chemically induced
3.
Int J Pharm ; 576: 118937, 2020 Feb 25.
Article in English | MEDLINE | ID: mdl-31816352

ABSTRACT

The present study characterized the buccal cavity-emptying and gastric-emptying kinetics of orally disintegrating tablets (ODTs) in fasted humans using gamma scintigraphy. 111Indium-diethylenetriaminepentaacetic acid and technetium-99 m-labeled ion exchange resin were used as a model soluble drug and insoluble pellet-type drug, respectively, and housed in ODTs. These ODTs were then administered to human subjects with or without ingestion of water, after which scintigraphic images were collected in order to characterize the buccal and gastric transit of the radioactivity. The oral disintegration of the ODTs was extremely rapid, with a mean time of ≤1 min. The buccal emptying of the radioactivity was most rapid for the ODT with a water-soluble radiolabel; however, the ODTs with water-insoluble radiolabels showed buccal emptying with median half-times of ≤2.5 min. The ODT with the soluble radiolabel in subjects without water ingestion showed the most rapid gastric emptying compared with the ODTs with the insoluble radiolabels, the gastric-emptying time of which was highly variable. Further, water ingestion did not markedly affect the gastric-emptying time of the tablets with the water-soluble model drug. The observations in the present clinical study will help clarify the in vivo performance of ODTs in humans.


Subject(s)
Cheek/physiology , Gastric Emptying/physiology , Gastric Mucosa/metabolism , Mouth Mucosa/metabolism , Oral Mucosal Absorption/physiology , Stomach/physiology , Tablets/metabolism , Administration, Oral , Chemistry, Pharmaceutical/methods , Cross-Over Studies , Gamma Rays , Humans , Ion Exchange Resins/administration & dosage , Mouth/metabolism , Radionuclide Imaging/methods , Solubility , Tablets/administration & dosage
4.
Mol Pharm ; 16(9): 3780-3790, 2019 09 03.
Article in English | MEDLINE | ID: mdl-31398041

ABSTRACT

A quantitative prediction of human pharmacokinetic (PK) profiles has become an increasing demand for the reduction of the clinical failure of drug formulations. The existing in vitro and in vivo correlation (IVIVC) methodology could achieve this goal, but the development of IVIVC for immediate release (IR) products is challenging. Herein, we report that for certain weakly acidic biopharmaceutical classification system (BCS) class II molecules (piroxicam, PIRO), physiologically based PK (PBPK) modeling could be used as a tool to quantitatively predict PK in beagle dogs and to conduct an interspecies extrapolation to humans. First, robust PBPK models were constructed in beagle dogs under both fasted and fed states. Then, a Z-factor model was integrated to assess the effect of in vitro dissolution rates on the in vivo PK performance, and the results illustrated that PIRO IR products had a much wider dissolution space than was anticipated by bioequivalence. In addition, the parameter sensitivity analysis (PSA) assay showed that good oral absorption was achieved only when the particle size was below 150 µm. Finally, the combined PBPK models were extrapolated to humans to specify a quality control strategy; this extrapolation constituted an extension of a biowaiver for PIRO IR formulations. The results showed that the developed method can be utilized to quantitatively predict human PK, which would be meaningful for future scale-up or postapproval changes.


Subject(s)
Chemistry, Pharmaceutical/methods , Drug Liberation/physiology , Models, Biological , Piroxicam/chemistry , Piroxicam/pharmacokinetics , Administration, Oral , Adult , Animals , Cross-Over Studies , Dogs , Drug Compounding , Fasting , Feeding Methods , Female , Healthy Volunteers , Humans , Hydrogen-Ion Concentration , Kinetics , Male , Oral Mucosal Absorption/physiology , Particle Size , Piroxicam/administration & dosage , Piroxicam/blood , Solubility , Therapeutic Equivalency , Young Adult
5.
Mol Pharm ; 16(9): 3948-3956, 2019 09 03.
Article in English | MEDLINE | ID: mdl-31361498

ABSTRACT

Many oral mucosal conditions cause considerable and prolonged pain that to date has been difficult to alleviate via topical delivery, and the use of injection causes many patients dental anxiety and needle-prick pain. Therefore, developing a noninjectable drug delivery system as an alternative administration procedure may vastly improve the health and wellbeing of these patients. Recent advances in the development of mucoadhesive electrospun patches for the direct delivery of therapeutics to the oral mucosa offer a potential solution, but as yet, the release of local anesthetics from this system and their uptake by oral tissue have not been demonstrated. Here, we demonstrate the fabrication of lidocaine-loaded electrospun fiber patches, drug release, and subsequent uptake and permeation through the porcine buccal mucosa. Lidocaine HCl and lidocaine base were incorporated into the electrospun patches to evaluate the difference in drug permeation for the two drug compositions. Lidocaine released from the lidocaine HCl-containing electrospun patches was significantly quicker than from the lidocaine base patches, with double the amount of drug released from the lidocaine HCl patches in the first 15 min (0.16 ± 0.04 mg) compared to that from the lidocaine base patches (0.07 ± 0.01 mg). The permeation of lidocaine from the lidocaine HCl electrospun patches through ex vivo porcine buccal mucosa was also detected in 15 min, whereas permeation of lidocaine from the lidocaine base patch was not detected. Matrix-assisted laser desorption ionization-mass spectrometry imaging was used to investigate localization of lidocaine within the oral tissue. Lidocaine in the solution as well as from the mucoadhesive patch penetrated into the buccal mucosal tissue in a time-dependent manner and was detectable in the lamina propria after only 15 min. Moreover, the lidocaine released from lidocaine HCl electrospun patches retained biological activity, inhibiting veratridine-mediated opening of voltage-gated sodium channels in SH-SY5Y neuroblastoma cells. These data suggest that a mucoadhesive electrospun patch may be used as a vehicle for rapid uptake and sustained anesthetic drug delivery to treat or prevent oral pain.


Subject(s)
Anesthetics/pharmacokinetics , Drug Delivery Systems/methods , Lidocaine/pharmacokinetics , Mouth Mucosa/drug effects , Oral Mucosal Absorption/physiology , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Voltage-Gated Sodium Channel Blockers/pharmacokinetics , Administration, Buccal , Anesthetics/administration & dosage , Animals , Cell Line, Tumor , Drug Liberation , Facial Pain/drug therapy , Humans , Lidocaine/administration & dosage , Mouth Mucosa/metabolism , Neuroblastoma/metabolism , Neuroblastoma/pathology , Swine , Tissue Distribution , Veratridine/pharmacology , Voltage-Gated Sodium Channel Agonists/pharmacology , Voltage-Gated Sodium Channel Blockers/administration & dosage
6.
Eur J Pharm Sci ; 130: 215-224, 2019 Mar 15.
Article in English | MEDLINE | ID: mdl-30716381

ABSTRACT

The present report demonstrates a quality by design approach to understand and optimize self-nanoemulsifying orodispersible films (SNEODF) of captopril for hypertension. A central composite experimental design was used to study the formulation parameters effects (primary emulsion, aqueous phase, and surfactant) on the film properties (globule size, film burst, adhesion, Young's moduli, disintegration time, tensile strength and dissolution). Principle component analysis (PCA) and principle component regression (PCR) were employed to identify and quantify the effects of formulation variables and physico-mechanical properties of the film on the drug permeability. PCA classified three distinct groups of film formulations based on their composition and properties. PCR quantified the impact of main variables, their interactions, and square effects on the drug permeability. The main effect of the aqueous phase exhibited a negative impact, while that of flux and tensile strength showed a positive impact on the permeability. Interactions of primary emulsions with disintegration time and tensile strength displayed a synergistic impact. Interactions of aqueous phase with flux, Young's moduli, and tensile strength, as well as between Young's moduli and tensile strength showed a significant positive effect on the permeability. A negative correlation of square effects of primary emulsion and flux, and a positive square effect of Young's moduli confirmed their non-linear influence on the drug permeability across porcine buccal mucosa. This research work demonstrates application of design of experiment and multivariate methods to achieve targeted product quality of captopril (SNEODF) having improved permeability and pH independent release profile.


Subject(s)
Captopril/pharmacokinetics , Drug Delivery Systems/methods , Emulsifying Agents/pharmacokinetics , Mouth Mucosa/drug effects , Oral Mucosal Absorption/drug effects , Administration, Oral , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics , Animals , Captopril/administration & dosage , Drug Evaluation, Preclinical/methods , Emulsifying Agents/administration & dosage , Mouth Mucosa/metabolism , Multivariate Analysis , Oral Mucosal Absorption/physiology , Swine
7.
Eur J Drug Metab Pharmacokinet ; 44(2): 169-177, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30328058

ABSTRACT

BACKGROUND AND OBJECTIVES: The importance of quercetin and flavonoids in the diet and as food supplements is well known, and literature studies support their potential use to treat several human diseases. Many beneficial properties have been described for quercetin, so much effort has been directed into overcoming the major drawbacks of this natural compound-its poor solubility and low oral absorption. The aims of this study were to compare a new food-grade lecithin-based formulation of quercetin, Quercetin Phytosome®, to unformulated quercetin in terms of solubility in simulated gastrointestinal fluids and oral absorption in a randomized crossover pharmacokinetic study of healthy volunteers. METHODS: The solubility of the new formulation was determined by in vitro incubation in simulated gastrointestinal fluids, and quercetin was detected by ultra performance liquid chromatography. A single-dose, randomized, six-sequence/three-period crossover clinical trial (3 × 3 × 3 crossover design) with a balanced carryover effect was conducted in healthy volunteers under fasting conditions. Twelve healthy volunteers of both sexes with an age range of 18-50 years were recruited; one dose of quercetin and two different doses of Quercetin Phytosome were administered orally as film-coated tablets. Pharmacokinetic samples were collected at twelve time points (from 0 h to 24 h) after administration, and quercetin levels were measured by HPLC/MS/MS. Data were analyzed using the Phoenix WinNonlin (v.6.4) software package, and the most significant pharmacokinetic parameters were calculated. Statistical analysis involved performing a two-way ANOVA with repeated measures followed by post hoc analysis (Tukey's test). RESULTS: Significant improvements in both in vitro solubility and oral absorption (in terms of both exposure and maximum concentration achieved) by healthy volunteers in a human clinical study were obtained with the Quercetin Phytosome formulation as compared to unformulated quercetin. CONCLUSIONS: A more soluble formulation of quercetin based on lecithin, Quercetin Phytosome, has recently been developed, and was found to facilitate the attainment of very high plasma levels of quercetin-up to 20 times more than usually obtained following a dose of quercetin-when the novel formulation was administered orally in human volunteers, and it did not have any notable side effects. These results suggest that Quercetin Phytosome allows the oral administration of quercetin in a safe and bioavailable manner, thus facilitating the effective utilization of this natural compound to treat various human diseases.


Subject(s)
Drug Delivery Systems/methods , Lecithins/administration & dosage , Lecithins/metabolism , Oral Mucosal Absorption/drug effects , Quercetin/administration & dosage , Quercetin/metabolism , Administration, Oral , Adolescent , Adult , Cross-Over Studies , Dose-Response Relationship, Drug , Fasting/metabolism , Female , Humans , Liposomes , Male , Middle Aged , Oral Mucosal Absorption/physiology , Young Adult
8.
J Pharm Sci ; 108(1): 326-336, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30300620

ABSTRACT

Spray-dried dispersions (SDDs) are an important technology for enhancing the oral bioavailability of poorly water-soluble drugs. To design an effective oral SDD formulation, the key rate-determining step(s) for oral drug absorption must be understood. This work combined in vivo and in vitro tests with in silico modeling to identify the rate-determining steps for oral absorption of belinostat SDDs made with 3 different polymers (PVP K30, PVP VA64, and HPMCAS-M). The goal was developing a belinostat SDD formulation that maximizes oral bioavailability (ideally matching the performance of a belinostat oral solution) and defining critical performance attributes for formulation optimization. The in vivo pharmacokinetic study with beagle dogs demonstrated that 1 of the 3 SDDs (PVP K30 SDD) matched the performance of the oral solution. In vitro data coupled with in silico modeling elucidated differences among the SDDs and supported the hypothesis that absorption of belinostat in the small intestine from the other 2 SDDs (PVP VA64 and HPMCAS-M) may be limited by dissolution rate or reduced drug activity (maximum concentration) in the presence of polymer. It was concluded that drug concentration in the stomach before emptying into the proximal intestine is a key factor for maximizing in vivo performance.


Subject(s)
Drug Compounding , Hydroxamic Acids/chemistry , Hydroxamic Acids/pharmacokinetics , Models, Biological , Oral Mucosal Absorption/physiology , Sulfonamides/chemistry , Sulfonamides/pharmacokinetics , Administration, Oral , Animals , Biological Availability , Computer Simulation , Dogs , Excipients/chemistry , Humans , Methylcellulose/analogs & derivatives , Methylcellulose/chemistry , Povidone/chemistry , Solubility
9.
AAPS PharmSciTech ; 19(3): 1392-1400, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29396734

ABSTRACT

Iloperidone is a second-generation antipsychotic drug which is used for the treatment of schizophrenia and has very low aqueous solubility and bioavailability. This drug also undergoes first-pass metabolism. The aim of this work is to formulate fast-dissolving sublingual films of iloperidone to improve its bioavailability. Sublingual films were prepared by solvent casting method. Hydroxypropyl methyl cellulose E5, propylene glycol 400, and transcutol HP were optimized using Box-Behnken three-level statistical design on the basis of disintegration time and folding endurance of films. Iloperidone:hydroxypropyl-ß-cyclodextrin kneaded complex was used in films instead of plain drug due to its low solubility. Optimized film was further evaluated for drug content, pH, dissolution studies, ex vivo permeation studies, and pharmacokinetic studies in rats. The optimized film disintegrated within 30 s. The in vitro dissolution of the film showed 80.3 ± 3.4% drug dissolved within first 5 min. In ex vivo permeation studies using sublingual tissue, flux achieved within first 15 min by film was around 117.1 ± 0.35 (mcg/cm2/h) which was ten times more than that of plain drug. This formulation showed excellent uniformity. AUC and Cmax of film were significantly higher (p < 0.001) as compared to plain drug and relative bioavailability of the films was 148% when compared to the plain drug. Thus, this study showed optimized fast-dissolving sublingual film to improve permeation and bioavailability of iloperidone. Fast-dissolving films will be customer-friendly approach for geadiatric schizophrenic patients.


Subject(s)
Drug Carriers/chemistry , Drug Carriers/metabolism , Drug Compounding/methods , Isoxazoles/chemistry , Isoxazoles/metabolism , Piperidines/chemistry , Piperidines/metabolism , Administration, Oral , Administration, Sublingual , Animals , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/chemistry , Antipsychotic Agents/metabolism , Biological Availability , Drug Carriers/administration & dosage , Hypromellose Derivatives/administration & dosage , Hypromellose Derivatives/chemistry , Hypromellose Derivatives/metabolism , Isoxazoles/administration & dosage , Male , Oral Mucosal Absorption/drug effects , Oral Mucosal Absorption/physiology , Piperidines/administration & dosage , Rats , Rats, Sprague-Dawley , Solubility
10.
Clin Hemorheol Microcirc ; 67(3-4): 489-498, 2017.
Article in English | MEDLINE | ID: mdl-28922146

ABSTRACT

INTRODUCTION: The outcome of patients in septic shock has been shown to be related to changes within the microcirculation. Modern imaging technologies are available to generate high resolution video recordings of the microcirculation in humans. However, evaluation of the microcirculation is not yet implemented in the routine clinical monitoring of critically ill patients. This is mainly due to large amount of time and user interaction required by the current video analysis software. The aim of this study was to validate a newly developed automated method (CCTools®) for microcirculatory analysis of sublingual capillary perfusion in septic patients in comparison to standard semi-automated software (AVA3®). METHODS: 204 videos from 47 patients were recorded using incident dark field (IDF) imaging. Total vessel density (TVD), proportion of perfused vessels (PPV), perfused vessel density (PVD), microvascular flow index (MFI) and heterogeneity index (HI) were measured using AVA3® and CCTools®. RESULTS: Significant differences between the numeric results obtained by the two different software packages were observed. The values for TVD, PVD and MFI were statistically related though. CONCLUSION: The automated software technique successes to show septic shock induced microcirculation alterations in near real time. However, we found wide degrees of agreement between AVA3® and CCTools® values due to several technical factors that should be considered in the future studies.


Subject(s)
Microcirculation/physiology , Oral Mucosal Absorption/physiology , Shock, Septic/therapy , Adult , Capillaries , Female , Humans , Male , Middle Aged , Software
12.
Biosci Biotechnol Biochem ; 81(7): 1300-1304, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28351211

ABSTRACT

Lactoferrin (LF) is produced by exocrine glands including salivary gland, and has various functions including infection defense. However, the transfer of LF from peripheral organs into the brain remains unclear. To clarify the kinetics of salivary LF (sLF), we investigated the consequences of sialoadenectomy and bovine LF (bLF) sublingual administration in rats. The salivary glands were removed from male Wistar rats, and we measured rat LF levels in the blood and brain at 1 week post-surgery. We also examined the transfer of LF into the organs of the rats after sublingual administration of bLF. Rat LF levels in the blood and brain were significantly reduced by sialoadenectomy. Sublingual bLF administration significantly increased bLF levels in the brain, which then decreased over time. These results indicate that LF is transferred from the sublingual mucosa to the brain, in which favorable effects of sLF on brain will be expected via the sublingual mucosa.


Subject(s)
Brain/metabolism , Lactoferrin/pharmacokinetics , Mouth Mucosa/metabolism , Salivary Glands/metabolism , Administration, Sublingual , Animals , Biological Transport , Cattle , Lactoferrin/blood , Male , Oral Mucosal Absorption/physiology , Rats , Rats, Wistar , Salivary Glands/surgery
13.
Anesth Analg ; 124(4): 1162-1167, 2017 04.
Article in English | MEDLINE | ID: mdl-27655276

ABSTRACT

BACKGROUND: Despite optimal preoxygenation, obese patients undergoing induction of general anesthesia exhibit significant hypoxemia after 2 to 4 minutes of apnea. Apneic oxygenation techniques can assist airway management by extending the safe apnea time. We hypothesized that a novel method of apneic oxygenation via the oral route would effectively prolong safe apnea in an obese surgical population. METHODS: In this open-label, parallel-arm, randomized-controlled efficacy trial, 40 ASA physical status I-II obese patients with body mass index (BMI) 30-40 were randomly assigned to standard care (n = 20) or buccal oxygenation (n = 20) during induction of total IV anesthesia. Buccal oxygen was administered via a modified 3.5-mm Ring-Adair-Elwyn (RAE) tube apposed to the left internal cheek. Prolonged laryngoscopy maintained apnea with a patent airway until SpO2 dropped below 95% or 750 seconds elapsed. The primary outcome was time to reach SpO2 < 95%. RESULTS: Patient characteristics were similar in both study arms. Recipients of buccal oxygenation were less likely to exhibit SpO2 < 95% during 750 seconds of apnea; hazard ratio 0.159 (95% confidence interval 0.044-0.226, P < .0001). Median (interquartile range [IQR]) apnea times with SpO2 ≥ 95% were prolonged in this group; 750 (389-750) versus 296 (244-314) seconds, P < .0001. CONCLUSIONS: Clinically important prolongation of safe apnea times can be achieved delivering buccal oxygen to obese patients on induction of anesthesia. This novel use of apneic oxygenation via the oral route may improve management of the difficult airway and overcome some of the limitations of alternative techniques.


Subject(s)
Airway Management/methods , Apnea/therapy , Laryngoscopy/methods , Obesity/therapy , Oral Mucosal Absorption , Oxygen Inhalation Therapy/methods , Administration, Buccal , Adult , Aged , Aged, 80 and over , Airway Management/instrumentation , Apnea/epidemiology , Female , Humans , Laryngoscopy/adverse effects , Laryngoscopy/instrumentation , Male , Middle Aged , Obesity/epidemiology , Oral Mucosal Absorption/physiology , Oxygen Inhalation Therapy/instrumentation , Young Adult
14.
J Control Release ; 240: 544-560, 2016 10 28.
Article in English | MEDLINE | ID: mdl-27520734

ABSTRACT

The majority of newly discovered oral drugs are poorly water soluble, and co-administration with lipids has proven effective in significantly enhancing bioavailability of some compounds with low aqueous solubility. Yet, lipid-based delivery technologies have not been widely employed in commercial oral products. Lipids can impact drug transport and fate in the gastrointestinal (GI) tract through multiple mechanisms including enhancement of solubility and dissolution kinetics, enhancement of permeation through the intestinal mucosa, and triggering drug precipitation upon lipid emulsion depletion (e.g., by digestion). The effect of lipids on drug absorption is currently not quantitatively predictable, in part due to the multiple complex dynamic processes that can be impacted by lipids. Quantitative mechanistic analysis of the processes significant to lipid system function and overall impact on drug absorption can aid in the understanding of drug-lipid interactions in the GI tract and exploitation of such interactions to achieve optimal lipid-based drug delivery. In this review, we discuss the impact of co-delivered lipids and lipid digestion on drug dissolution, partitioning, and absorption in the context of the experimental tools and associated kinetic expressions used to study and model these processes. The potential benefit of a systems-based consideration of the concurrent multiple dynamic processes occurring upon co-dosing lipids and drugs to predict the impact of lipids on drug absorption and enable rational design of lipid-based delivery systems is presented.


Subject(s)
Drug Carriers/chemistry , Lipids/chemistry , Models, Biological , Oral Mucosal Absorption , Pharmaceutical Preparations/administration & dosage , Administration, Oral , Biological Availability , Digestion/physiology , Drug Liberation , Humans , Oral Mucosal Absorption/physiology , Pharmaceutical Preparations/chemistry , Pharmaceutical Preparations/metabolism , Solubility
15.
Clin Hemorheol Microcirc ; 64(2): 205-212, 2016 Nov 25.
Article in English | MEDLINE | ID: mdl-27258200

ABSTRACT

Anemia in pregnant women is associated with increased maternal and perinatal mortality and represents an important economic burden in many developing countries. Our goal was to evaluate the impact of anemia on the capillary network during pregnancy. Therefore, we compared microcirculatory parameters of anemic pregnant study participants to that of non-anemic pregnant women employing sublingual microcirculation video imaging technology and novel automated video analysis software.Non-anemic (n = 7) and anemic (n = 44) pregnant women were enrolled in the study at second and third trimesters. Video imaging was applied to the sublingual mucosal surface in five visual fields. The resultant videos were analyzed automatically, avoiding observer bias. Total vessel density (TVD), perfused vessel density (PVD) and proportion of perfused vessels (PPV) were calculated by the software. Both, mean TVD and PVD were significantly increased in the anemic pregnant group, while the PPV was not significantly different. Significant negative correlations were observed between haemoglobin (Hb) levels and both, TVD and PVD. Haemoglobin level seems to play an important determinant role in restructuring the capillary network. An effect that could compensate the impaired tissue oxygen delivery associated with anemia during pregnancy.


Subject(s)
Hemoglobins/metabolism , Oral Mucosal Absorption/physiology , Adult , Female , Humans , Microcirculation , Pregnancy
16.
Mol Pharm ; 13(5): 1551-63, 2016 05 02.
Article in English | MEDLINE | ID: mdl-27019088

ABSTRACT

Mucoadhesive buccal films (MBFs) provide an innovative way to facilitate the efficient site-specific delivery of active compounds while simultaneously separating the lesions from the environment of the oral cavity. The structural diversity of these complex multicomponent and mostly multiphase systems as well as an experimental strategy for their structural characterization at molecular scale with atomic resolution were demonstrated using MBFs of ciclopirox olamine (CPX) in a poly(ethylene oxide) (PEO) matrix as a case study. A detailed description of each component of the CPX/PEO films was followed by an analysis of the relationships between each component and the physicochemical properties of the MBFs. Two distinct MBFs were identified by solid-state NMR spectroscopy: (i) at low API (active pharmaceutical ingredient) loading, a nanoheterogeneous solid solution of CPX molecularly dispersed in an amorphous PEO matrix was created; and (ii) at high API loading, a pseudoco-crystalline system containing CPX-2-aminoethanol nanocrystals incorporated into the interlamellar space of a crystalline PEO matrix was revealed. These structural differences were found to be closely related to the mechanical and physicochemical properties of the prepared MBFs. At low API loading, the polymer chains of PEO provided sufficient quantities of binding sites to stabilize the CPX that was molecularly dispersed in the highly amorphous semiflexible polymer matrix. Consequently, the resulting MBFs were soft, with low tensile strength, plasticity, and swelling index, supporting rapid drug release. At high CPX content, however, the active compounds and the polymer chains simultaneously cocrystallized, leaving the CPX to form nanocrystals grown directly inside the spherulites of PEO. Interfacial polymer-drug interactions were thus responsible not only for the considerably enhanced plasticity of the system but also for the exclusive crystallization of CPX in the thermodynamically most stable polymorphic form, Form I, which exhibited reduced dissolution kinetics. The bioavailability of CPX olamine formulated as PEO-based MBFs can thus be effectively controlled by inducing the complete dispersion and/or microsegregation and nanocrystallization of CPX olamine in the polymer matrix. Solid-state NMR spectroscopy is an efficient tool for exploring structure-property relationships in these complex pharmaceutical solids.


Subject(s)
Adhesives/chemistry , Adhesives/metabolism , Ethylene Oxide/chemistry , Mouth Mucosa/metabolism , Polyethylene Glycols/chemistry , Pyridones/chemistry , Biological Availability , Chemistry, Pharmaceutical/methods , Ciclopirox , Crystallization/methods , Drug Liberation/physiology , Magnetic Resonance Spectroscopy/methods , Nanoparticles/chemistry , Oral Mucosal Absorption/physiology , Polyethylene Glycols/metabolism , Polymers/chemistry , Solubility
17.
Nutr J ; 14: 114, 2015 Oct 29.
Article in English | MEDLINE | ID: mdl-26514332

ABSTRACT

BACKGROUND: Vitamin D deficiency has been proposed to contribute to the development of malabsorption diseases. Despite this, the vitamin D status of these patients is often neglected. The objective of the present work was to compare the absorption of vitamin D3 through the oral route by comparing a 1000 IU soft gelatin capsule and a 500 IU buccal spray (delivering 1000 IU in two spray shots) in healthy subjects and in patients with malabsorption disease. METHODS: An open label, randomized, two-periods, two-way cross over study was conducted, first in healthy subjects (n = 20) and then in patients with malabsorption syndrome (n = 20). The study participants were equally divided and received either of the treatments (buccal spray, n = 7; soft gelatin capsule, n = 7; control, n = 6) in Period I for 30 days. After washout of another 30 days, the treatments were changed in crossover fashion in Period II. Fasting blood samples were collected to measure baseline 25-hydroxyvitamin D [25(OH)D] levels in all participants at day 0 (Screening visit), day 30 (completion of period I), day 60 (end of wash out and initiation of period II) and day 90 (completion of period II). Safety was evaluated by hematology and biochemistry analyses. Statistical analyses was performed using differences of mean and percentage change from baseline of 25(OH)D levels between two formulation by two tailed Paired t-test with 95% confidence interval. RESULTS: In healthy subjects, the mean increase in serum 25(OH)D concentration was 4.06 (95% CI 3.41, 4.71) ng/ml in soft gelatin capsule group and 8.0 (95% CI 6.86, 9.13) ng/ml in buccal spray group after 30 days treatment (p < 0.0001). In patients with malabsorption disease, the mean increase in serum 25(OH)D concentration was 3.96 (95% CI 2.37, 5.56) ng/ml in soft gelatin capsule group and 10.46 (95% CI 6.89, 14.03) ng/ml in buccal spray group (p < 0.0001). CONCLUSION: It can be concluded from the results that the buccal spray produced a significantly higher mean serum 25(OH)D concentration as compared to the soft gelatin capsule, in both healthy subjects as well as in patients with malabsorption syndrome over a period of 30 days administration in a two way cross over study. Treatments were well tolerated by both subject groups TRIAL REGISTRATION: CTRI/2013/06/003770.


Subject(s)
Cholecalciferol/administration & dosage , Cholecalciferol/pharmacokinetics , Malabsorption Syndromes/metabolism , Administration, Buccal , Adult , Capsules , Cross-Over Studies , Female , Gelatin , Humans , Intestinal Absorption/physiology , Male , Oral Mucosal Absorption/physiology , Treatment Outcome , Vitamins/administration & dosage , Vitamins/pharmacokinetics
18.
J Nanosci Nanotechnol ; 15(8): 5559-65, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26369117

ABSTRACT

In order to improve the oral absorption of curcumin, curcumin-loaded lipid cubic liquid crystalline nanoparticles were prepared and evaluated in vitro and in vivo. The hot and high-pressure homogenization method was used to prepare the nanoparticles. The formulation and process were optimized by uniform design with drug loading and entrapment efficiency as index, and physicochemical properties were also investigated. Spherical nanoparticles were observed under transmission electron microscope (TEM), with average particle size of 176.1 nm, zeta potential of -25.19 mV, average drug loading of (1.5 ± 0.2)% and entrapment efficiency of (95 ± 1.8)%. The in vitro release of curcumin from the nanoparticle formulation showed a sustained property, while the pharmacokinetics results after oral administration of curcumin loaded lipid cubic liquid crystalline nanoparticles in rat showed that the oral absorption of curcumin fitted one-compartment model and relative bioavailability was 395.56% when compared to crude curcumin. It can be concluded from these results that the lipid cubic liquid crystalline nanoparticles, as carriers, can markedly improve the oral absorption of curcumin.


Subject(s)
Curcumin/administration & dosage , Curcumin/pharmacokinetics , Delayed-Action Preparations/chemical synthesis , Liquid Crystals/chemistry , Nanocapsules/chemistry , Oral Mucosal Absorption/physiology , Absorption, Physicochemical , Animals , Curcumin/chemistry , Delayed-Action Preparations/administration & dosage , Diffusion , Male , Materials Testing , Metabolic Clearance Rate , Nanocapsules/administration & dosage , Nanocapsules/ultrastructure , Particle Size , Rats , Rats, Wistar , Surface Properties
19.
J Biomed Nanotechnol ; 11(3): 469-77, 2015 Mar.
Article in English | MEDLINE | ID: mdl-26307829

ABSTRACT

This study aimed to enhance the solubility of a poorly water-soluble drug, pranlukast, as well as its transport across Madin-Darby canine kidney (MDCK) monolayers, thus increasing its oral bioavailability. To accomplish this aim, we prepared a pranlukast-phospholipid complex (PPC). The PPC was prepared by solvent-evaporation and characterized by transmission electron microscopy (TEM), X-ray diffraction (XRD), infrared (IR) spectroscopy, and solubilization studies. The solubility of pranlukast in the PPC was increased from 1.03 ± 0.32 µg/ml to 160.63 ± 2.72 µg/ml with a yield of 96.39 ± 1.20% when the PPC was prepared under optimal conditions. TEM images showed that the PPC particles had a spherical shape. XRD data indicated that pranlukast in the PPC was either in an amorphous form or in a dispersed molecular distribution. IR analysis confirmed the interaction between pranlukast and the phospholipids. The transport mechanism of the PPC and non-complexed pranlukast across MDCK cells was measured and was observed to be significantly greater for the former than for the latter. The in vivo bioavailability of the PPC in rats hastened the onset of pranlukast-induced therapeutic effects, with C(max) and AUC increases of 21.88- and 28.64-fold, respectively, compared with raw crystals. In addition, an in vivo imaging method was used to corroborate that the PPC exhibited rapid circulatory distribution and gastrointestinal tract accumulation. These results indicate that PPC appears to be a promising drug delivery system for pranlukast, improving drug absorption and decreasing side effects by reducing the required oral dose.


Subject(s)
Chromones/administration & dosage , Chromones/pharmacokinetics , Nanocapsules/chemistry , Oral Mucosal Absorption/physiology , Phospholipids/chemistry , Administration, Oral , Animals , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/chemistry , Anti-Asthmatic Agents/pharmacokinetics , Chromones/chemistry , Diffusion , Dogs , Madin Darby Canine Kidney Cells , Male , Metabolic Clearance Rate , Mice , Mice, Inbred BALB C , Nanocapsules/ultrastructure , Organ Specificity , Particle Size , Rats , Rats, Sprague-Dawley , Solubility , Tissue Distribution
20.
Crit Care ; 19: 241, 2015 Jun 04.
Article in English | MEDLINE | ID: mdl-26041462

ABSTRACT

INTRODUCTION: Esmolol may efficiently reduce heart rate (HR) and decrease mortality during septic shock. An improvement of microcirculation dissociated from its macrocirculatory effect may a role. The present study investigated the effect of esmolol on gut and sublingual microcirculation in a resuscitated piglet model of septic shock. METHODS: Fourteen piglets, anesthetized and mechanically ventilated, received a suspension of live Pseudomonas aeruginosa. They were randomly assigned to two groups: the esmolol (E) group received an infusion of esmolol, started at 7.5 µg⋅kg(-1)⋅min(-1), and progressively increased to achieve a HR below 90 beats⋅min(-1). The control (C) group received an infusion of Ringer's lactate solution. HR, mean arterial pressure (MAP), cardiac index (CI), stroke index (SI), systemic vascular resistance (SVR), arterio-venous blood gas and lactate were recorded. Oxygen consumption (VO2), delivery (DO2) and peripheral extraction (O2ER) were computed. Following an ileostomy, a laser Doppler probe was applied on ileal mucosa to monitor gut microcirculatory laser Doppler flow (GMLDF). Videomicroscopy was also used on ileal mucosa and sublingual areas to evaluate mean flow index (MFI), heterogeneity, ratio of perfused villi and proportion of perfused vessels. Resuscitation maneuvers were performed following a defined algorithm. RESULTS: Bacterial infusion induced a significant alteration of the gut microcirculation with an increase in HR. Esmolol produced a significant time/group effect with a decrease in HR (P <0.004) and an increase in SVR (P <0.004). Time/group effect was not significant for CI and MAP, but there was a clear trend toward a decrease in CI and MAP in the E group. Time/group effect was not significant for SI, O2ER, DO2, VO2, GMLDF and lactate. A significant time/group effect of ileal microcirculation was found with a lower ileal villi perfusion (P <0.025) in the C group, and a trend toward a better MFI in the E group. No difference between both groups was found regarding microcirculatory parameters in the sublingual area. CONCLUSIONS: Esmolol provided a maintenance of microcirculation during sepsis despite its negative effects on macrocirculation. Some parameters even showed a trend toward an improvement of the microcirculation in the gut area in the esmolol group.


Subject(s)
Disease Models, Animal , Gastrointestinal Tract/drug effects , Microcirculation/drug effects , Propanolamines/pharmacology , Shock, Septic/drug therapy , Sublingual Gland/drug effects , Animals , Female , Gastrointestinal Tract/blood supply , Gastrointestinal Tract/physiology , Microcirculation/physiology , Oral Mucosal Absorption/drug effects , Oral Mucosal Absorption/physiology , Propanolamines/therapeutic use , Random Allocation , Shock, Septic/physiopathology , Sublingual Gland/blood supply , Sublingual Gland/physiology , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...